🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Colorectal cancer is being diagnosed in a greater number of patients younger than 50 than ever before. Get your colonoscopies at age 45 per new guidelines and PREVENT this deadly disease! #coloncancer #prevention #cancer x.com/coloncancertas…

Bardelli & co. investigate the radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer patients. ow.ly/gMwZ30kTqCY

Excited to see the FDA approve nivo + ipi for MSI-High #crcsm. Congrats to the MD Anderson Cancer Center team that led this great work!! Have seen this combo work wonders in my patients with #colorectalcancer!!. news.bms.com/press-release/…

Great new trial MD Anderson Cancer Center for patients with metastatic colon or rectal cancer to the lung! #coloncancer #rectalcancer #cancer #mdanderson #clinicaltrials Mara Antonoff, MD, FACS Van Morris, MD

So exciting to see BRAF/EGFR/MEK combo get #breakthrough designation by FDA for #BRAF mut #colorectalcancer. MAJOR advance for aggressive #crcsm subtype. Happy MD Anderson Cancer Center participated on this important study. Congrats Scott Kopetz & @ArrayBiopharma! bit.ly/2MfzRgG

My mentor, Scott Kopetz, sharing exciting updated results from the BEACON study finding no OS benefit with triplet regimen of enco + cetux + bini vs enco + cetux alone.

So proud of my friend and colleague, Van Morris, MD for leading a great discussion at GI ASCO!

Words cannot express the impact Dr. V had on her patients and colleagues. She was a beautiful physician and a loving mother. I will forever be grateful for her mentorship and guidance. Rest In Peace, Dr. V. You will be deeply missed.

Inspiring stories like this, and incredible and brave patients like ⁦Ben Terry⁩ keep me fighting every day against this terrible disease. #fightcrc ⁦MD Anderson Cancer Center⁩ kplctv.com/2022/11/05/met…

Use of serial ctDNA in metastatic #CRC to refine patient selection, reduce toxicity from chemotherapy & evaluate emerging resistance mechanisms that may lead the way to novel therapeutic strategies. doi.org/10.1158/1078-0… Christine Parseghian, MD Scott Kopetz MD Anderson Cancer Center #INTERCEPT

🎉⭐️Major implications for understanding CRC biology & rechallenge studies! Resistance Mechanisms to Anti-EGFR Therapy in RAS/RAF Wildtype Colorectal Cancer Vary by Regimen & Line of Therapy pubmed.ncbi.nlm.nih.gov/?term=36351210 ParseghianC DrJasonWillis VanMorrisMD skopetz MDAndersonNews

Had the honor of co-chairing and presenting about novel therapeutics in colorectal cancer this weekend at the ESMO - Eur. Oncology conference in Barcelona! So many exciting advances, but so much left to do! MD Anderson Cancer Center Fight Colorectal Cancer #ESMO2024

BREAKWATER Ph3 showing an incredible improvement in ORR by 21% and doubling of the duration of response with the addition of FOLFOX to enco+cetux in BRAFV600E MT CRC. 👏🏻🙌🏻 Congrats to my forever mentor Scott Kopetz for changing the standard of care in 1L CRC!!#ASCOGI25 Fight Colorectal Cancer

What a way to close ASCO #ASCOGI25! Have an informal gathering of friends to celebrate everyone’s achievements! #promotions #leadership #research CONGRATS 👏 👏 Christine Parseghian, MD Van Morris, MD Arvind Dasari, MD, MS with my forever friends Dr. David Fogelman and the AMAZING Lara Robinson, MS.

The incidence of young-onset colorectal cancer is frighteningly increasing over the last few decades. I share a few reasons in this interview, while telling the story of a fearless fighter patient of mine, graciously sharing his story. MD Anderson Cancer Center #CRC healthline.com/health-news/ea…

What are the most provoking and practice-changing studies being presented in colorectal and anal cancer at #ASCO25? Our Dr. Christine Parseghian discussed BREAKWATER, CheckMate 8HW, and CODEBREAK 101 in the Highlights of the Day I session. Christine Parseghian, MD ASCO #EndCancer

Dr Christine Parseghian, MD kicks off #BoA25 with the best in #crcsm trials from #ASCO25 starting off with the #BREAKWATER data #GIonc OncoAlert🚨 ASCO PallOnc Community of Practice #OncoAlertAF Emre Yekedüz Fadi Haddad, MD Al-Ola A Abdallah MD (USMIRC) Erman Akkus Bárbara Melão, MD, PhD Alizée Camps - - Maléa Fabio Martinelli Dr. Iván R. González

Dr Christine Parseghian, MD with a beautiful summary after her #crcsm trials for #BoA25 about the #future of our field including more #biomarker 🎯 therapies, tumor #plasticity and overcoming #resistance and universal #molecular testing #GIonc #BestofASCO OncoAlert🚨 #OncoAlertAF